TNFRSF10A and cancer: Activation of apoptosis signaling by DRs remains an attractive strategy for therapeutic applications since recombinant human (rh)Apo2L/TRAIL and agonistic antibodies directed against either DR4 or DR5 have shown activity in vitro and in vivo against a range of cancers, and combinations of DR agonists with conventional chemotherapeutics have shown promise in preclinical testing [34]–[37].